- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03461432
Personalised Cognitive Remediation Therapy (pCRT) (pCRT)
Testing the Feasibility and Acceptability of a New Personalised Form of Cognitive Remediation Therapy (pCRT) for People With Psychosis.
Cognitive deficits have been shown to have negative impact on social functioning and functional goals such as ability to work and perform daily tasks in people with schizophrenia. There is evidence that Cognitive Remediation Therapy, a form of psychological therapy, is effective in improving cognition and functioning but there is still a limited understanding of what influence people's different response to this therapy. A tailored treatment is likely to be more effective because it will adapt to service users' unique characteristics.
The investigators are planning a study exploring at the feasibility and acceptability of novel form of Cognitive Remediation Therapy which is personalised (pCRT) to the person individual characteristics. The personalised therapy will consist of task practice using computerized Cognitive Remediation software (i.e. called CIRCuiTS). The knowledge gathered in this work will contribute to develop the next generation of personalised treatment approaches for people with schizophrenia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- a range of 18-65 years
- English speaking or with a good knowledge of the language
- a diagnosis of schizophrenia or schizoaffective disorder according to the DSM- V
- at least one year contact with mental health services,
- a deficit (of at least one standard deviation below the mean) in at least one cognitive domain out of these three cognitive domains: memory, executive function and information processing.
Exclusion Criteria:
- Planned medication change
- Diagnosis of learning disability
- Presence of cognitive deficits related to organic causes or head injury
- Primary diagnosis of substance dependence
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Personalised Cognitive Remediation Therapy (pCRT)
A case-control study design with pre- and post-therapy assessment, comparing a group of participants with schizophrenia who received standard CRT, with a similar group of participants receiving pCRT.
|
Cognitive Remediation Therapy (CRT) is a psychological therapy that has been developed with a general immediate focus on improving impaired cognitive domains but ultimately aimed at improving social and functional outcomes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of intervention (including acceptance rates, drop outs)
Time Frame: 3 months post baseline assessment
|
Feasibility estimates of delivering the intervention including acceptance rates, drop outs.
|
3 months post baseline assessment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of intervention (Satisfaction)
Time Frame: 3 months post baseline assessment
|
Questionnaire of Satisfaction
|
3 months post baseline assessment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 231245
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia Schizoaffective
-
Teva Branded Pharmaceutical Products R&D, Inc.RecruitingSchizophrenia, Schizoaffective DisorderUnited States
-
Hoffmann-La RocheTerminatedSchizophrenia, Schizoaffective DisorderUnited States, Spain, Japan, Ukraine
-
Central Institute of Mental Health, MannheimCompletedSchizophrenia, Schizoaffective DisorderGermany
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompletedSchizophrenia and Schizoaffective DisorderHungary, United States, Argentina, Canada, Czech Republic, Estonia, France, Latvia, Lithuania
-
AmgenCompletedSchizophrenia or Schizoaffective DisorderUnited States
-
AmgenCompletedSchizophrenia or Schizoaffective DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompletedSchizophrenia and Schizoaffective Disorder
-
University of Sao PauloUnknownSchizophrenia or Schizoaffective DisorderBrazil
-
Hoffmann-La RocheCompletedSchizophrenia, Schizoaffective DisorderUnited States, Japan, Ukraine, Russian Federation
-
Centre for Addiction and Mental HealthOntario Ministry of Health and Long Term CareRecruitingSchizophrenia, Schizoaffective DisorderCanada
Clinical Trials on Cognitive Remediation Therapy
-
Yale UniversityCompletedCancer | Cancer of the ProstateUnited States
-
Gemma Garrido GarcíaCompleted
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Mental DisordersUnited States
-
Fraser HealthMinistry of Social Development and Poverty Reduction, British ColumbiaCompletedSchizophrenia and Related Disorders | Psychotic DisorderCanada
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Centre for Addiction and Mental HealthCompletedSchizophrenia | Cognitive Deficit | Cognitive Remediation | Functional Impairment | Late Life SchizophreniaCanada
-
Hospital Clinic of BarcelonaInstituto de Salud Carlos III; Centro de Investigación Biomédica en Red de...Completed
-
Stanford UniversityNational Institute of Mental Health (NIMH)CompletedAnorexia NervosaUnited States
-
Hospital Clinic of BarcelonaNational Alliance for Research on Schizophrenia and Depression; Instituto de...Unknown